Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Moderna

Nasdaq Leads as Tech Stages Late-Week Comeback: Stock Market Today

Oracle stock boosted the tech sector on Friday after the company became co-owner of TikTok's U.S. operations.

Kiplinger

Trump’s FDA plans to put a ‘black box’ warning on COVID vaccines: report

Black boxes are the FDA’s most serious warning sign and are usually placed on opioid products

The Independent UK

Is Moderna Stock Underperforming the Nasdaq?

Moderna has continued to underperform the Nasdaq Composite over the past year, and analysts remain cautious about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Walmart, Intuit, The Gap, SanDisk And Moderna: Why These 5 Stocks Are On Investors' Radars Today

Despite Nvidia’s strong quarterly performance, the broader market struggled on Thursday. A robust U.S. jobs report, showing non-farm payrolls rising by 119,000 in September, dampened hopes for a December rate cut, as traders now see a 64% chance of the Fed holding rates steady.

Benzinga

What Are Wall Street Analysts’ Target Price for Moderna Stock?

Are Wall Street analysts favoring Moderna’s stock?

Barchart

mRNA Vaccine Maker Moderna Lowers R&D Spending, Tightens Sales Forecast

Moderna Inc. (NASDAQ:MRNA) reported a third-quarter loss of 51 cents, beating the expected loss of $2.02, a turnaround from an income of 3 cents a year ago.

Benzinga

Moderna Q3 2025 Earnings Call Transcript

Moderna, Inc (NASDAQ:MRNA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below. MRNA is building positive momentum. Watch the momentum here This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visithttps://www.benzinga.com/apis/for a consultation. Operator…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Pfizer COVID-19 vaccine sales drop 25% after confusing government guidance on the shot

Previously, fall is when Americans would typically receive their vaccines

The Independent UK

One molecule could usher revolutionary medicines for cancer, diabetes and genetic disease — but the US is turning its back on it

The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of uncertainty, scientists worry that revolutionary treatments for cancer, immune dysfunction and genetic disease may be left on the lab bench.

LiveScience

Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection

Moderna, Inc. (NASDAQ:MRNA) revealed topline results on Wednesday from a Phase 3 trial evaluating the efficacy of mRNA-1647, the company’s investigational cytomegalovirus (CMV) vaccine. CMV is a herpes virus. Those who are pregnant or have compromised immune systems are most at risk from CMV.

Benzinga

Moderna Earnings Preview: What to Expect

Moderna is expected to announce its third-quarter results next month, and analysts expect a significant loss per share.

Barchart

Moderna Stock Is at a Crossroads. Is the Path Ahead One of Profit or Pain for MRNA?

Moderna’s story is far from over, but it needs patience and successful execution.

Barchart

Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant Patients

Moderna Inc. (NASDAQ:MRNA) announced on Sunday that its clinical, safety, and translational data from its Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab in patients with checkpoint inhibitor-resistant/refractory (CPI-R/R) melanoma will be presented at the 2025 European Society for Medical Oncology Congress.

Benzinga

What do Musk, Microsoft’s CEO and the head of Zoom all have in common? The H-1B visa that is now in Trump’s crosshairs

IN FOCUS: From Elon Musk and Satya Nadella to the co-founder of Moderna, it’s not just tycoons in Silicon Valley who have benefited from the controversial work visa now in Donald Trump’s crosshairs, writes Io Dodds

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Moderna Stock Is Rallying Wednesday: What's Driving The Action?

Moderna Inc (NASDAQ:MRNA) stock is trading higher Wednesday afternoon, lifted by positive sentiment across the pharmaceutical sector. The rally follows a landmark agreement Tuesday between Pfizer Inc (NYSE:PFE) and the Trump administration to lower prescription drug prices.

Benzinga

Moderna Stands By UK As Pharma Giants Criticize Pricing, UK Secures First Onshore mRNA Vaccine Production Centre

Moderna, Inc.‘s (NASDAQ: MRNA) UK chief Darius Hughes defended Britain's drug pricing policies after the country was branded the "worst in Europe."

The Independent UK

Moderna takes swipe at Trump as it opens new UK factory: ‘A country that still believes in vaccination’

New opening comes amid a rise in anti-vax attitudes within the Trump administration

The Guardian - UK

Moderna boss defends UK in drug-pricing row as he opens £150m Oxfordshire facility

‘We’re here to invest,’ says Darius Hughes as he calls comments by other pharma companies ‘a little harsh’

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Moderna opens new vaccine facility in boost for UK pharmaceutical industry

The plant in Oxfordshire can make up to 100 million doses per year.

Benzinga

Flagship Pioneering, Creator Of Moderna, Launches Extuitive With $20M To Reinvent Consumer Products Using AI Shoppers

Flagship Pioneering, the Cambridge venture firm known for creating Moderna (NASDAQ:MRNA), last Thursday unveiled a new startup called Extuitive with $20 million in seed funding.

Benzinga

Moderna's COVID-19 Vaccine Update Boosts Antibodies 16-Fold, Data Shows

Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE (COVID-19 Vaccine, mRNA), which targets the LP.8.1 variant of SARS-CoV-2.

AAP

Vaccine site could save Australia billions in pandemic

Australia's first sovereign mRNA vaccine facility could give the nation a shot in the arm against the next pandemic, an independent report says.

International Business Times UK

Moderna Shares Surge After Recording Positive Phase 4 Prelim Data on COVID-19 Drug

Moderna shares rose by over 4% on a mixed Tuesday for US equities ahead of the US Federal Reserve's rate cut decision today.

Benzinga

What's Going On With Moderna Stock Wednesday?

Moderna Inc (NASDAQ:MRNA) shares are flat Wednesday morning after a nearly 5% surge on Tuesday. Here’s what investors need to know.

Benzinga

Moderna Stock Is Moving Higher Tuesday: Here's Why

Moderna, Inc. (NASDAQ:MRNA) shares are up nearly 5% on Tuesday after the company announced positive preliminary immunogenicity data for its 2025-2026 Spikevax formula, which targets the new LP.8.1 variant of COVID-19.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations